BioSpace News Archive

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that Craig Collard, Chief Executive Officer of Heron, will participate in a fireside chat on Wednesday, April 10, 2024, at 11:00 AM ET at the 23rd Annual Needham Virtual Healthcare Conference.

Pyxis Oncology, Inc. reported that Pyxis Oncology’s Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 39,680 shares of Pyxis Oncology’s common stock and stock options to purchase an aggregate of 49,600 shares of Pyxis Oncology’s common stock to a newly hired employee.

Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported recent business highlights and financial results for the fourth quarter and full-year ended December 31, 2023.

Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today provided corporate updates and reported its financial results for the fourth quarter and year ended December 31, 2023.

Sirona Biochem Corp. announces the voting results from its Annual General Meeting of Shareholders, held in Vancouver, British Columbia on March 28, 2024.

Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, announced it granted an inducement award on March 28, 2024.

Trinity Biotech plc will report financial results for the fourth quarter and fiscal year 2023 on Thursday, April 4, 2024 at 8:00 AM ET.

Willow Biosciences Inc. (“Willow” or the “Company”) (TSX: WLLW) (OTCQB: CANSF) is pleased to announce its financial and operating results for the three months and year ended December 31, 2023, and filing of its Annual Information Form (“AIF”).

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced it will host a webcast on Thursday, April 11, 2024, at 8:00 a.m. ET to discuss initial proof of concept data on ELVN-001 and the evolving chronic myeloid leukemia (CML) landscape.

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, announced results from a special meeting of stockholders held March 27, 2024.